Many analysts have commented how Israel’s successful high tech economy is a fact driven by necessity. Never was this more true than in the fields of medical devices and applications.

Specifically, look at the example of wound healing, a subject that reaches out to the civilian and heavy military markets alike in Israel. Estimates calculate the value of the global market at around US$9 billion.

And here’s the catch. Many of the global players with something significant to offer are Israeli:

Israel will have the world’s largest company for burn and chronic wound treatments, if all goes according to plan in a complex merger deal between Clal Biotechnology Industries Ltd. (TASE: CBI) portfolio companies MediWound Ltd. and Polyheal Ltd., which will come under the control of Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA). Under the proposed deal, MediWound will acquire full control of Polyheal, and Teva will gradually increase its stake in MediWound to 51%.

There are several other, but lesser known, Israeli companies, which operate in the field. One is called Cupron. It offers a copper-based platform technology, which is known to support skin regeneration. Could it make stitches in the skin an irrelevant subject?

These discoveries, shoved into the media limelight, come at a time, when there are growing shouts for economies to boycott Israeli products. The hypocrisy of such a world campaign is drawn out by these very products.

Can you imagine an organiser for these unilateral moves, which are often basted on hate turning round, saying: “I refuse Israeli treatment on my skin”? What nonsense!